We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to ...

In high-risk patients with pulmonary arterial hypertension, Merck ’s fusion protein therapeutic Winrevair reduced the ...

Results from the Phase III ZENITH trial show that Winrevair lowered the risk of all-cause death, lung transplantation, and ...

Winrevair (sotatercept-csrk), compared to placebo, reduced the risk of all-cause death, lung transplantation, and hospitalization.

Merck (NYSE:MRK) recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock performance over the past month tells a different story ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Merck & Co has announced the first presentation of full results from the Phase III ZENITH trial of Winrevair ...

In the news last week, US Center for Biologics Evaluation and Research (CBER) Dr Peter Marks quit his post after reported ...

WINREVAIR is currently approved in more than 40 countries based on the results from the STELLAR trial. Merck announced in January 2025 that the Phase 3 HYPERION study evaluating WINREVAIR when ...

Winrevair (sotatercept-csrk) significantly reduced the risk of death, lung transplant, or hospitalization in people with PAH.

But AstraZeneca stock fell in line with pharma stocks. Merck (NYSE:MRK) recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock performance ...